The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
How does the prognostic outlook for patients with double-hit lymphoma impact disease management?
Featured:
Narendranath EpperlaDuring the COLYM 2022 Annual Meeting, the Lymphoma Hub spoke with Narendranath Epperla, The Ohio State University, Columbus, US. We asked, How does the prognostic outlook for patients with double-hit lymphoma impact disease management?
How does the prognostic outlook for patients with double-hit lymphoma impact disease management?
Narendranath starts by defining double-hit lymphoma, explaining that patients with this classification are often refractory to the standard-of care front-line treatment R-CHOP. Narendranath then discusses outcome data for patients receiving dose-adjusted R-EPOCH, the typical front-line treatment for double- and triple-hit lymphoma.
Narendranath goes on to addresses the potential of more effective treatments than dose-adjusted R-EPOCH for these patients, reviewing studies that have evaluated the efficacy and toxicity of lenalidomide combined with R-CHOP, R-EPOCH, and dose-adjusted R-EPOCH. Promising results from early phase studies investigating other approaches, such as venetoclax combined with dose-adjusted R-EPOCH and CAR T-cell therapy, are also discussed.